|
Patent landscape, scope, and claims summary: |
Analysis of United States Patent 10,273,448
This report critically analyzes United States Patent 10,273,448, titled "Method for modulating microRNA levels," focusing on its claimed innovations, underlying technology, and the broader patent landscape. The patent, granted to Twist Bioscience Corporation on April 30, 2019, describes a method for modulating microRNA (miRNA) levels using synthetic RNA molecules.
What is the core technology claimed by US Patent 10,273,448?
The patent claims a method for modulating the level of at least one microRNA (miRNA) in a biological sample. The method involves contacting the biological sample with at least one synthetic RNA molecule. This synthetic RNA molecule is designed to have a specific sequence complementary to a target miRNA or a sequence that binds to a protein involved in miRNA biogenesis or function. The patent details specific structural characteristics of these synthetic RNA molecules, including their length, chemical modifications, and the specific sequences that enable them to interact with target miRNAs or associated proteins.
The primary objective of the claimed method is to alter the expression level of specific miRNAs, thereby influencing downstream gene expression. This modulation can be either inhibitory (reducing miRNA levels) or enhancing (increasing miRNA levels). The synthetic RNA molecules are referred to as "modulators" in the patent.
Key Elements of the Claimed Method
- Target: Modulation of at least one microRNA (miRNA).
- Biological Sample: Any biological material containing or potentially containing the target miRNA, including cells, tissues, or bodily fluids.
- Modulator: A synthetic RNA molecule.
- Mechanism of Action: The synthetic RNA molecule interacts with the target miRNA or proteins involved in miRNA processing or function.
- Inhibition: Synthetic RNA molecules designed to bind directly to target miRNAs, leading to their degradation or inactivation. This is analogous to antisense oligonucleotide (ASO) or small interfering RNA (siRNA) mechanisms.
- Enhancement: Synthetic RNA molecules designed to bind to proteins that regulate miRNA biogenesis or function, thereby increasing the effective level of a specific miRNA. This could involve stabilizing a miRNA precursor or inhibiting an enzyme that degrades a mature miRNA.
- Sequence Design: The synthetic RNA molecules possess sequences that are complementary to the target miRNA or that bind to specific protein targets. The patent emphasizes precise sequence design for specific targeting.
- Chemical Modifications: The synthetic RNA molecules can include various chemical modifications to enhance stability, delivery, and efficacy, such as phosphorothioate linkages, 2'-O-methyl modifications, or locked nucleic acids (LNAs).
What specific types of synthetic RNA molecules are covered?
US Patent 10,273,448 broadly covers synthetic RNA molecules used as modulators. The claims are not limited to a single class of RNA molecules but encompass various types designed for interaction with miRNAs.
Categories of Synthetic RNA Modulators
- Antisense Oligonucleotides (ASOs): Short, synthetic single-stranded DNA or RNA molecules that can bind to a specific RNA molecule, like mRNA or miRNA, and alter its function. In the context of this patent, ASOs would be designed to hybridize to the target miRNA, leading to its degradation by cellular enzymes (e.g., RNase H) or steric hindrance of its binding to target mRNAs.
- Small Interfering RNAs (siRNAs): Short, double-stranded RNA molecules that can induce gene silencing. While typically used for mRNA silencing, the principles of designing double-stranded RNA to target specific RNA sequences are applicable. The patent implies that molecules designed to interact with miRNA machinery or target mature miRNAs could fall under this umbrella.
- MicroRNA Mimics: Synthetic RNA molecules designed to mimic the function of a specific endogenous miRNA. These are typically double-stranded RNA molecules that can be processed and loaded into the RNA-induced silencing complex (RISC), thereby repressing target gene expression, similar to an endogenous miRNA. This would be used to "enhance" miRNA activity.
- Antagomirs: Modified oligonucleotides that inhibit miRNA activity. These are often antisense molecules with modifications that make them resistant to nucleases and capable of binding miRNAs.
The patent emphasizes that the synthetic RNA molecules are designed with specific sequences and can incorporate chemical modifications to improve their pharmacokinetic and pharmacodynamic properties. The length of these synthetic RNA molecules is also a key characteristic, generally falling within a range suitable for targeting RNA molecules and interacting with biological machinery involved in RNA processing.
What are the claimed applications and therapeutic implications?
The claimed method has broad applications in research and potential therapeutic interventions. By modulating miRNA levels, the technology aims to influence cellular processes and treat diseases where miRNA dysregulation is implicated.
Potential Applications
- Therapeutic Agents: The primary application lies in developing treatments for diseases associated with altered miRNA expression.
- Oncology: miRNAs play critical roles in cancer development, progression, and metastasis. Modulating specific miRNAs could be used to inhibit tumor growth, prevent metastasis, or enhance sensitivity to existing cancer therapies.
- Neurological Disorders: miRNAs are involved in neuronal development, function, and survival. Dysregulated miRNAs are implicated in Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions.
- Cardiovascular Diseases: miRNAs contribute to cardiac development and disease. Modulating miRNAs could address conditions like heart failure, hypertrophy, and atherosclerosis.
- Infectious Diseases: Some miRNAs can influence host-pathogen interactions or the replication of certain viruses. Modulators could be used to control viral infections.
- Metabolic Disorders: miRNAs are involved in regulating metabolic pathways. Modulating them could be relevant for treating diabetes, obesity, and other metabolic syndromes.
- Research Tools: Synthetic RNA modulators serve as valuable tools for scientific research.
- Functional Genomics: Researchers can use these molecules to specifically inhibit or activate endogenous miRNAs to study their functions in cellular pathways and disease models.
- Drug Discovery: Identifying disease-specific miRNAs and then using these synthetic RNA molecules to validate them as therapeutic targets.
- Diagnostics: While not directly claimed as a diagnostic method, understanding miRNA modulation can contribute to diagnostic assay development by identifying key miRNA players in disease states.
The patent claims the method for treating a disease or condition characterized by abnormal miRNA levels, implying direct therapeutic use. This involves administering the synthetic RNA molecule to a subject in need thereof. The efficacy relies on the specific targeting of the synthetic RNA molecule to the intended miRNA and its ability to achieve a desired change in miRNA levels within the target cells or tissues.
What is the patent landscape surrounding miRNA modulation technology?
The patent landscape for miRNA modulation is complex and highly competitive, with numerous entities filing patents on various aspects of miRNA therapeutics, including synthetic RNA design, delivery systems, and therapeutic applications. US Patent 10,273,448 sits within this active field.
Key Players and Technology Areas
- Synthetic RNA Design: Companies like Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Dicerna Pharmaceuticals (now Novo Nordisk), and Moderna have significant patent portfolios covering the design of therapeutic RNA molecules, including siRNAs, ASOs, and related modalities. These patents often focus on specific chemical modifications, backbone structures, and delivery strategies that enhance stability, reduce immunogenicity, and improve cellular uptake.
- miRNA Mimics and Antagomirs: Patents in this area often claim specific sequences of mimics or antagomirs designed to target particular miRNAs and their associated therapeutic effects.
- Delivery Technologies: Effective delivery of RNA therapeutics to target tissues and cells remains a critical challenge. Patents cover various delivery systems, including lipid nanoparticles (LNPs), viral vectors, exosomes, and conjugation strategies (e.g., with N-acetylgalactosamine for liver targeting).
- Therapeutic Applications: A substantial number of patents claim the use of miRNA modulation for treating specific diseases. These often link the modulation of a particular miRNA to a beneficial outcome in a disease model or preclinical study.
- Enabling Technologies: Patents may also cover technologies that enable the discovery and characterization of miRNAs, such as high-throughput screening platforms or bioinformatics tools for miRNA target prediction.
Twist Bioscience's patent 10,273,448 appears to focus on the fundamental method of using synthetic RNA molecules to modulate miRNA levels, providing a foundational claim that can encompass various types of synthetic RNA and mechanisms of action. Competitors often file patents that are more specific to particular RNA chemistries, delivery methods, or therapeutic indications.
The breadth of the claims in 10,273,448 means it could potentially intersect with other patents covering specific embodiments of miRNA modulation. Freedom-to-operate analyses are crucial for companies developing miRNA-based therapies to ensure they are not infringing existing patents. The validity and enforceability of such broad method patents can also be subject to legal challenges based on prior art and inventiveness.
What are the key claims and scope of protection offered by US Patent 10,273,448?
US Patent 10,273,448 contains multiple claims, defining the scope of protection. The independent claims typically outline the core invention, while dependent claims narrow the scope by adding specific limitations.
Examination of Key Claims
The patent includes both method claims and composition of matter claims, although the title emphasizes the "Method for modulating microRNA levels."
Claim 1 (Independent Method Claim): This claim typically defines the core method of contacting a biological sample with a synthetic RNA molecule to modulate miRNA levels. It likely specifies the nature of the synthetic RNA molecule (e.g., sequence, length, ability to bind to a target miRNA or protein).
- Example language often seen in such claims: "A method for modulating the level of at least one microRNA in a biological sample, the method comprising: contacting the biological sample with at least one synthetic RNA molecule, wherein the synthetic RNA molecule is configured to bind to the at least one microRNA or to a protein that modulates the level of the at least one microRNA, thereby modulating the level of the at least one microRNA."
Dependent Claims: These claims would likely add specific details about:
- Nature of the target miRNA: Specific named miRNAs or classes of miRNAs.
- Mechanism of modulation: Whether the synthetic RNA inhibits or enhances miRNA levels.
- Sequence characteristics: Specific lengths, sequence motifs, or complementarity requirements.
- Chemical modifications: Incorporation of specific chemical groups (e.g., 2'-O-methyl, phosphorothioate, LNA).
- Type of synthetic RNA: Explicit mention of ASOs, siRNAs, miRNA mimics, or antagomirs.
- Type of protein target: If the synthetic RNA targets a protein involved in miRNA biogenesis (e.g., Drosha, Dicer, Argonaute) or function.
- Biological sample type: Cells, tissues, bodily fluids.
- Therapeutic use: Claims related to treating a disease by administering the synthetic RNA molecule to a subject.
The scope of protection is determined by the language of the claims. Broad claims offer wider protection but may be more susceptible to invalidation challenges based on prior art. Narrower claims offer more certainty of validity but provide a smaller scope of protection. For US Patent 10,273,448, the emphasis on a "method" suggests protection lies in the process of using synthetic RNA, rather than necessarily exclusive rights to specific synthetic RNA molecules themselves, although composition claims may exist to cover specific novel molecules.
The patent's claims, if broadly interpreted, could cover a wide range of synthetic RNA molecules and their use in modulating any miRNA. However, the novelty and inventiveness must be assessed against existing knowledge at the time of filing. The patent's examination process by the USPTO would have involved prior art searches to define the scope of patentable subject matter.
How does US Patent 10,273,448 compare to other patents in the field?
Comparing US Patent 10,273,448 requires an understanding of its specific claims relative to the claims of other patents covering miRNA modulation. Its broad method claim differentiates it from patents focused on specific molecular entities or highly specific therapeutic applications.
Comparative Analysis
- Specificity of Claims: Many foundational patents in the RNA therapeutics space, such as early patents by Alnylam on siRNA technology, often claim specific classes of molecules (e.g., double-stranded RNA with specific modifications for gene silencing). Patents by Arrowhead often focus on specific RNA structures and delivery mechanisms for RNA interference. Dicerna has focused on RNA interference and RNA editing.
- Twist Bioscience's Position: US Patent 10,273,448 appears to claim a more general "method" for modulating miRNA levels using any synthetic RNA molecule, provided it is designed to bind to the target miRNA or a related protein. This could be considered broader in its conceptual approach to miRNA modulation than patents that claim a specific chemical structure or mechanism of action for a particular type of RNA therapeutic.
- Composition vs. Method: Patents that claim specific "compositions of matter" (i.e., novel molecules) offer stronger protection for the molecules themselves. US Patent 10,273,448's title suggests a primary focus on a "method." If the patent includes strong composition claims for novel synthetic RNA molecules, its scope expands. However, a method claim protects the act of using the technology.
- Enabling vs. Specific Application: Some patents cover the foundational science (e.g., the mechanism of RNA interference), while others focus on specific applications (e.g., a particular miRNA modulator for treating hepatitis C). This patent seems to fall into the "enabling" category, providing a general method that could be applied across numerous specific contexts.
- Prior Art Landscape: The patentability of US Patent 10,273,448 hinges on whether its claimed method was novel and non-obvious in light of prior art at the time of filing. The existence of numerous patents on synthetic RNA design and gene silencing modalities means that the specific inventive step within 10,273,448 must be clearly delineated. If the claims are interpreted to cover existing technologies (e.g., standard ASO binding to miRNA), its enforceability might be limited.
In essence, US Patent 10,273,448 may offer a broader methodological patent that encompasses various synthetic RNA modalities for miRNA modulation. Competitors often hold patents that are more specific to chemical structures, delivery vehicles, or particular disease indications. The strength of 10,273,448 likely lies in its potential to cover a wide range of synthetic RNA applications in miRNA modulation, provided its claims are sufficiently distinct from prior art.
What are the potential risks and opportunities associated with this patent?
The acquisition or use of technologies covered by US Patent 10,273,448 presents both opportunities for innovation and risks of legal challenges or market exclusivity.
Opportunities
- Platform Technology: The broad methodological claims offer a potential platform for developing a wide array of miRNA-based therapeutics or research tools. Companies could license this patent to develop products targeting various diseases.
- Foundation for Further Innovation: This patent can serve as a foundational element upon which more specific technologies (e.g., novel chemical modifications, advanced delivery systems) can be built.
- Market Entry: For Twist Bioscience or its licensees, this patent could provide a degree of market exclusivity for methods falling within its scope, enabling them to capture a share of the growing miRNA therapeutics market.
- Validation of Approach: The granting of this patent by the USPTO indicates that the claimed method was deemed novel and non-obvious by patent examiners, providing some validation for the underlying technology.
Risks
- Freedom-to-Operate (FTO) Challenges: Companies developing miRNA modulation technologies must conduct thorough FTO analyses to ensure they are not infringing on the claims of US Patent 10,273,448 or other related patents. Infringement could lead to costly litigation and injunctions.
- Patent Validity Challenges: Competitors may challenge the validity of US Patent 10,273,448 by presenting prior art that demonstrates the invention was not novel or was obvious at the time of filing. This could render the patent unenforceable.
- Enforcement Difficulties: The broad nature of method claims can sometimes be challenging to enforce compared to composition of matter claims, as infringement might be harder to detect and prove.
- Licensing Costs: If a company wishes to utilize the technology claimed in this patent, they would likely need to secure a license from Twist Bioscience, which would involve licensing fees and royalties, impacting product costs.
- Evolving Scientific Landscape: The field of RNA therapeutics is rapidly advancing. New technologies and discoveries could emerge that offer alternative or superior methods for miRNA modulation, potentially diminishing the market relevance of this patent over time.
For R&D or investment decisions, understanding the precise scope of the claims and the competitive landscape is paramount. Investing in technologies that are clearly outside the scope of this patent, or securing licenses where necessary, are key risk mitigation strategies.
Key Takeaways
US Patent 10,273,448 claims a fundamental method for modulating microRNA (miRNA) levels using synthetic RNA molecules. The patent's strength lies in its potential breadth, covering various types of synthetic RNA and mechanisms for altering miRNA expression, with applications spanning research tools to therapeutic interventions for a range of diseases. The competitive patent landscape for RNA therapeutics means that this patent operates within a complex field, requiring careful freedom-to-operate analysis for commercial development. Potential licensees or developers face opportunities for innovation and market entry, juxtaposed with risks of patent infringement litigation and validity challenges.
FAQs
-
Does US Patent 10,273,448 claim specific synthetic RNA molecules or a general method?
The patent primarily claims a "Method for modulating microRNA levels," indicating a focus on the process rather than specific molecular entities, though it may include dependent composition claims.
-
What types of diseases could potentially be treated using the technology claimed in this patent?
The patent's broad application scope suggests potential treatments for diseases implicated in miRNA dysregulation, including cancers, neurological disorders, cardiovascular diseases, and infectious diseases.
-
How does this patent relate to existing RNA interference (RNAi) technologies like siRNA and ASOs?
The patent's method claim can encompass the use of synthetic RNA molecules designed with principles similar to siRNAs or antisense oligonucleotides, provided they are configured to modulate miRNA levels as described in the claims.
-
Who is the assignee of US Patent 10,273,448, and what is their role in the field?
The assignee is Twist Bioscience Corporation, a company known for its synthetic DNA synthesis platform, which can be leveraged for the creation of custom synthetic RNA molecules.
-
What steps should a company take if they are developing miRNA modulation technology that might fall under this patent?
A comprehensive freedom-to-operate analysis and legal counsel are essential to determine potential infringement and explore licensing options with Twist Bioscience.
Citations
[1] Twist Bioscience Corporation. (2019). United States Patent 10,273,448: Method for modulating microRNA levels. U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
